Impact of Coenzyme Q10 and Selenium on Seminal Fluid and Semen Antioxidant Status

Male Infertility Clinical Trial

Official title:

Impact of Coenzyme Q10 and Selenium on Seminal Fluid Parameters and Antioxidant Status in Men With Idiopathic Infertility

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03834831
• Other study ID #: EC/2018/8866
• Status: Completed
• Phase: N/A
• Start date: June 1, 2018
• Est. completion date: January 10, 2019

Study information

• Verified date: March 2019
• Source: University of Sumer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study was conducted to assess the impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in infertile men.

Description:

The aim of this study was to assess the impact of coenzyme Q10 and selenium on seminal fluid parameters and antioxidant status in infertile men with idiopathic oligoasthenoteratospermia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: January 10, 2019
• Est. primary completion date: October 31, 2018
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• History of infertility of at least 12 months despite regular unprotected intercourse.

• Oligoasthenoteratospermia was diagnosed by semen analysis showing abnormal sperm concentration (<15 million/ml), progressive motility (<32%), total motility (<40%) and morphology (<30% WHO criteria) as defined by WHO manual for semen analysis 2010

Exclusion Criteria:

• Azoospermia,

• Varicocele,

• Genital tract infection,

• Cryptorchidism,

• Testicular trauma or scrotal surgery,

• Endocrine disorder,

• Systemic illness,

• Smoking

• The presence of female factor

Related Conditions & MeSH terms

• Infertility
• Infertility, Male
• Male Infertility

Intervention

Dietary Supplement:
• Coenzyme Q10
Coenzyme Q10
• Selenium
Selenium

Locations

Country	Name	City	State
Iraq	Fertility Unit, Babyl	Hilla

Sponsors (1)

Lead Sponsor	Collaborator
University of Sumer

Country where clinical trial is conducted

Iraq, 

References & Publications (2)

Alahmar AT. The effects of oral antioxidants on the semen of men with idiopathic oligoasthenoteratozoospermia. Clin Exp Reprod Med. 2018 Jun;45(2):57-66. doi: 10.5653/cerm.2018.45.2.57. Epub 2018 Jun 29. Review. — View Citation

Alshahrani S, Aldossari K, Al-Zahrani J, Gabr AH, Henkel R, Ahmad G. Interpretation of semen analysis using WHO 1999 and WHO 2010 reference values: Abnormal becoming normal. Andrologia. 2018 Mar;50(2). doi: 10.1111/and.12838. Epub 2017 Aug 3. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Semen volume (WHO 2010 guidelines)	Semen volume in ml	3 months
Primary	Sperm concentration in semen (WHO 2010 guidelines)	Sperm concentration in million/ml	3 months
Primary	Sperm motility in semen (WHO 2010 guidelines)	Sperm motility (%)	3 months
Primary	Sperm morphology in semen (WHO 2010 guidelines)	Normal sperm morphology (%)	3 months
Primary	Seminal plasma TAC (Colorimetric assays)	Seminal plasma total antioxidant capacity in mmol/ml	3 months
Primary	Seminal plasma CAT (Colorimetric assays)	Seminal plasma catalase in U/ml	3 months
Primary	Seminal plasma SOD (Colorimetric assays)	Superoxide dismutase in U/ml	3 months